The combination of Roche’s investigational drug, giredestrant, with Pfizer’s Ibrance didn’t lead to a statistically significant improvement among patients with advanced breast cancer.
Source link
About The Author
Roche Breast-Cancer Treatment Falls Short of Primary Goal in Late-Stage Study